Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.
Overall, patients with HER2-positive breast cancer do well with available regimens. Using trastuzumab (Herceptin) in combination with chemotherapy for this patient population significantly improves disease-free and overall survival, states Tolaney.
How to best add pertuzumab (Perjeta) to the treatment landscape and which patients should receive it are significant questions that many physicians would like to see answered, explains Tolaney.
